BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 208 filers reported holding BRIDGEBIO PHARMA INC in Q2 2021. The put-call ratio across all filers is 1.95 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,635 | +59.0% | 61,976 | +3.7% | 0.00% | – |
| Q2 2023 | $1,028 | +12.2% | 59,756 | +8.3% | 0.00% | – |
| Q1 2023 | $916 | +80.7% | 55,201 | -17.0% | 0.00% | – |
| Q4 2022 | $507 | -99.9% | 66,522 | -20.1% | 0.00% | – |
| Q3 2022 | $828,000 | +1.1% | 83,286 | -7.7% | 0.00% | – |
| Q2 2022 | $819,000 | +21.9% | 90,197 | +36.2% | 0.00% | – |
| Q1 2022 | $672,000 | -4.0% | 66,224 | +57.7% | 0.00% | – |
| Q4 2021 | $700,000 | -66.4% | 41,986 | -5.6% | 0.00% | – |
| Q3 2021 | $2,085,000 | -93.7% | 44,493 | -91.8% | 0.00% | -100.0% |
| Q2 2021 | $33,111,000 | -11.3% | 543,165 | -10.4% | 0.00% | -25.0% |
| Q1 2021 | $37,329,000 | +1637.0% | 605,990 | +1905.7% | 0.00% | – |
| Q4 2020 | $2,149,000 | +111.5% | 30,214 | +11.6% | 0.00% | – |
| Q3 2020 | $1,016,000 | +73.4% | 27,073 | +50.8% | 0.00% | – |
| Q2 2020 | $586,000 | +14.0% | 17,955 | +1.4% | 0.00% | – |
| Q1 2020 | $514,000 | – | 17,711 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $60,317,000 | 40.05% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $308,746,000 | 6.20% |
| M28 Capital Management LP | 513,300 | $5,102,000 | 5.33% |
| GREAT POINT PARTNERS LLC | 1,050,000 | $10,437,000 | 2.51% |
| Octagon Capital Advisors LP | 933,743 | $9,281,000 | 1.60% |
| HHLR ADVISORS, LTD. | 5,362,014 | $53,298,000 | 1.40% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $264,613,000 | 1.22% |
| Cormorant Asset Management, LP | 1,469,179 | $14,604,000 | 1.02% |
| Fernwood Investment Management, LLC | 204,550 | $2,033,000 | 0.86% |
| TANG CAPITAL MANAGEMENT LLC | 585,424 | $5,819,000 | 0.71% |